세계의 인간화 마우스 및 쥐 모델 시장 예측(-2030년) : 유형별, 최종사용자별, 용도별, 지역별

Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030

US $ 4,950 ￦ 6,767,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,650 ￦ 9,091,000

PDF (5-user License)

PDF 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,150 ￦ 11,141,000

PDF (Corporate License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 이용 인원에 제한은 없으나, 국내에 있는 사업장만 해당되며, 해외 지점 등은 포함되지 않습니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000 ￦ 13,671,000

PDF (Global License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. (100% 자회사는 동일 기업으로 간주됩니다.) 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계의 인간화 마우스·쥐 모델 시장 규모는 2025년 2억 7,620만 달러에서 2030년에는 4억 980만 달러에 달할 것으로 예측되며, CAGR은 8.2%로 높을 것으로 기대되고 있습니다.

이 시장은 제약 및 바이오 제약 기업의 R&D 투자 증가로 인해 높은 CAGR로 강력하게 성장하고 있습니다. R&D 파이프라인이 확대됨에 따라 희귀질환 및 희귀의약품에 대한 연구 구상과 더불어 분석 시험 아웃소싱에 대한 요구가 증가하고 있습니다. 또한 자체적으로 의약품을 개발하는 데 드는 높은 비용도 이러한 추세에 박차를 가하고 있습니다. 기술 발전, 새로운 신약 개발 기술, 특허 만료, 최종사용자의 전문 검사 서비스에 대한 수요 증가로 인해 업계는 건전한 성장 기회를 얻을 수 있을 것으로 예측됩니다.

조사 범위
조사 대상연도	2024-2030년
기준연도	2024년
예측 기간	2024-2030년
검토 단위	금액(100만 달러)
부문	유형별, 최종사용자별, 용도별, 지역별
대상 지역	북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카

유형별로 인간화 마우스 및 쥐 모델 시장은 인간화 마우스 모델과 인간화 쥐 모델로 구분되며, 2024년에는 인간화 마우스 모델이 시장 매출 측면에서 가장 높은 점유율을 차지할 것으로 예측됩니다. 또한 이 부문은 예측 기간 중 가장 빠른 CAGR로 성장할 것으로 예측됩니다. 세포 기반 인간화 마우스 모델에 대한 수요 증가가 이 부문의 성장에 기여하고 있습니다. 이러한 모델은 잠재적 신약의 안전성 및 효능 분석, 면역 종양학, 감염성 질환, 이식편 대 숙주 질환의 장기 연구 등 다양한 용도로 활용되고 있습니다.

인간화 마우스/쥐 모델 시장은 용도별로 종양학, 면역 및 감염학, 신경과학, 조혈학, 독성학, 기타 용도로 구분됩니다. 면역/감염증 분야는 매출액 기준 시장 2위 분야입니다. 마우스 모델은 실험적 지식의 생리적 타당성을 평가하는 데 도움이 되므로 면역학 및 염증 연구에 사용됩니다. 마우스 모델은 마우스 유전체을 무작위로 또는 특정 영역에서 적절히 변화시킬 수 있으므로 면역학적 과정에 대한 상세한 연구가 가능합니다.

최종사용자별로 시장은 제약 및 생명공학 기업, CRO 및 CDMO, 학술 및 연구기관으로 구분되며, 2024년에는 제약 및 생명공학 기업이 이 부문을 지배할 것으로 예측됩니다. 제약/바이오 기업이 인간화 마우스/쥐 모델 시장에서 가장 높은 점유율을 차지하는 이유는 혁신적인 의약품 개발을 위한 지출 증가와 맞춤형 의료에 대한 선호도가 높아졌기 때문입니다. 그러나 CRO &CDMO 부문은 예측 기간 중 가장 높은 성장률을 나타낼 것으로 예상되는데, 이는 제약 및 생명공학 기업이 의약품 개발을 위한 전임상시험 및 연구 활동을 이 최종사용자 부문에 위탁하는 경우가 증가하고 있기 때문입니다.

지역별로는 북미, 유럽, 아시아태평양, 라틴아메리카, 중동 및 아프리카로 구분됩니다. 북미는 2024년 인간화 마우스 및 쥐 모델 시장을 장악했으며, 예측 기간 중에도 독주할 것으로 예측됩니다. 미국이 북미 시장을 주도하고 있으며, 주요 진출기업의 존재가 그 원동력이 되고 있습니다. 이 시장의 큰 점유율은 주로 생명과학 연구에 대한 자금 지원 증가, mAbs 및 바이오시밀러에 대한 연구 증가에 기인합니다. 또한 암 발병률 증가도 시장 성장을 지원할 것으로 예측됩니다.

세계의 인간화 마우스·쥐 모델 시장에 대해 조사했으며, 유형별, 최종사용자별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 가격 분석
• 공급망 분석
• 밸류체인 분석
• 에코시스템 분석
• 투자와 자금조달 시나리오
• 기술 분석
• 특허 분석
• 무역 분석
• 2025-2026년의 주요 컨퍼런스와 이벤트
• 규제 상황
• Porter's Five Forces 분석
• 주요 이해관계자와 구입 기준
• 인간화 마우스·쥐 모델 시장에 대한 AI의 영향

제6장 인간화 마우스·쥐 모델 시장(유형별)

• 서론
• 인간화 마우스 모델
• 인간화 쥐 모델

제7장 인간화 마우스·쥐 모델 시장(최종사용자별)

• 서론
• 제약·바이오테크놀러지 기업
• CRO·CDMO
• 학술연구기관

제8장 인간화 마우스·쥐 모델 시장(용도별)

• 서론
• 종양학
• 면역학과 감염증
• 신경과학
• 독물학
• 조혈
• 기타

제9장 인간화 마우스·쥐 모델 시장(지역별)

• 서론
• 북미
  • 북미의 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 유럽의 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 아시아태평양의 거시경제 전망
  • 중국
  • 일본
  • 인도
  • 한국
  • 호주
  • 기타
• 라틴아메리카
  • 제약회사와 바이오테크놀러지 기업의 존재감이 커지며 시장이 확대
  • 라틴아메리카의 거시경제 전망
• 중동
  • 시장의 성장을 지원하는 국가 의약품 시장의 성장
  • 중동의 거시경제 전망
• 아프리카
  • 성장하는 제약 업계가 시장의 성장을 지원한다.
  • 아프리카의 거시경제 전망

제10장 경쟁 구도

• 서론
• 주요 참여 기업의 전략/강점
• 매출 분석, 2020-2024년
• 시장 점유율 분석, 2024년
• 기업 평가와 재무 지표
• 브랜드/제품 비교
• 기업 평가 매트릭스 : 주요 참여 기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 경쟁 시나리오

제11장 기업 개요

• 주요 참여 기업
  • CHARLES RIVER LABORATORIES
  • THE JACKSON LABORATORY
  • INOTIV
  • GENOWAY
  • TACONIC BIOSCIENCES, INC.
  • JSR CORPORATION
  • CHAMPIONS ONCOLOGY, INC.
  • JANVIER LABS
  • VITALSTAR BIOTECHNOLOGY
  • INGENIOUS TARGETING LABORATORY
  • HARBOUR BIOMED
  • ONCODESIGN SERVICES
  • PHARMATEST SERVICES
• 기타 기업
  • OZGENE PTY LTD.
  • CLEA JAPAN, INC.
  • ALTOGEN LABS
  • REACTION BIOLOGY
  • TRANSCURE BIOSERVICES
  • CYAGEN
  • ARAGEN LIFE SCIENCES LTD.
  • BIOCYTOGEN
  • GEMPHARMATECH

제12장 부록

KSA

영문 목차

영문목차

The global humanized mouse and rat model market is anticipated to reach USD 409.8 million in 2030 from USD 276.2 million in 2025, with a significant CAGR of 8.2%. The market is growing strongly at a high CAGR due to rising R&D investments of pharmaceutical and biopharmaceutical firms. As the pipeline of R&D expands, the requirement for outsourcing analytical testing is set to rise, in addition to the research initiatives on rare diseases and orphan drugs. Furthermore, the high costs of in-house drug development have also contributed to this trend. Industry players will likely witness healthy growth opportunities due to technological advancements, new drug discovery techniques, patent expirations, and rising demand for specialized testing services among end users.

Scope of the Report
Years Considered for the Study	2024-2030
Base Year	2024
Forecast Period	2024-2030
Units Considered	Value (USD million)
Segments	Type, Application, and End User
Regions covered	North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

"Humanized mouse model segment dominated the type segment in 2024"

Based on type, the humanized mouse and rat model market has been segmented into humanized mouse models and humanized rat models. In 2024, humanized mouse models will have garnered the highest share in terms of revenue in the market. This segment is also expected to grow with the fastest CAGR through the forecast period. An increase in demand for cell-based humanized mouse models has contributed to the segment's growth. These models are utilized in various applications, including the analysis of the safety and effectiveness of potential new drugs and in long-term studies in immuno-oncology, infectious diseases, and graft-versus-host disease.

"The immunology & infectious diseases segment accounted for the second largest share of the market in 2024"

The humanized mouse and rat model market is segmented based on application into oncology, immunology & infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The immunology & infectious diseases segment is the second largest segment in the market in terms of revenue. Mouse models are used in immunology and inflammation studies as they help assess the physiological relevance of an experimental finding. Mouse models allow suitable alterations in the mouse genome at random or in specific regions, enabling a detailed study of immunological processes.

"Pharmaceutical & Biotechnology Companies will likely record the highest CAGR during the forecast period"

Based on the end users, the market is segmented into pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes. Pharmaceutical & biotechnology companies dominated the segment in 2024. The largest share of pharmaceutical and biotechnology companies in the humanized mouse and rat model market is due to the rising expenditure for innovative drug development and the growing preference for personalized medicine. However, the CROs & CDMOs segment is expected to register the highest growth during the forecast period due to the increasing number of pharmaceutical & biotechnology companies outsourcing preclinical studies and research activities for drug development to this end user segment.

"US to record the highest CAGR during the forecast period"

The market is segmented by region into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America dominated the humanized mouse and rat model market in 2024 and is estimated to continue dominating during the forecast period. The US leads the North American market, driven by the presence of key players. The large share of the market is primarily driven by the rising funding for life sciences research and growing research on mAbs and biosimilars. The growing incidence of cancer is also expected to support market growth.

In-depth interviews were conducted with chief executive officers (CEOs), directors, and other executives from various key organizations operating in the humanized mouse and rat model market.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: C-level Executives - 45%, Directors - 30%, and Others - 25%
• By Region: North America - 45%, Europe - 30%, Asia Pacific - 20%, Latin America - 3% and Middle East & Africa - 2%

Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Taconic Biosciences, Inc. (US), JSR Corporation (US) (Crown Biosciences), Champions Oncology, Inc. (US), CLEA Japan Inc. (Japan), genOway (France), Inotiv (US), Janvier Labs (France), Altogen Labs (US), Vitalstar Biotechnology (China), Ingenious Targeting Laboratory (US), Reaction Biology (US), Harbour BioMed (Netherlands), Oncodesign Services (France), Pharmatest Services (Finland), Ozgene Pty Ltd. (Australia), TransCure bioServices (France), Cyagen Biosciences (US), Aragen Life Sciences Ltd. (India), GemPharmatech (China), and Biocytogen (US) are some of the key players in the humanized mouse and rat model market.

Research Coverage:

Humanized mouse and rat model market report is segmented based on type {[(humanized mouse models {genetic humanized mouse models and cell-based humanized mouse models (CD34 humanized mouse models, PBMC humanized mouse models, and BLT humanized mouse models)]} and humanized rat models), application (oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications, end user (pharmaceutical & biotechnology companies, CROs & CDMOs, and academic & research institutes), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East, Africa).

The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the humanized mouse and rat model market. A comprehensive analysis of the key players in the industry has been conducted to offer insights into their business overviews, products, key strategies, collaborations, partnerships, and agreements. This includes information about recent product launches, collaborations, acquisitions, and humanized mouse and rat model market developments.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the humanized mouse and rat model and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (rising use of humanized models in drug discovery research, emerging preclinical applications of humanized mouse models, government-funded initiatives for cancer research, and increasing R&D activities in the pharmaceutical & biotechnology industry), restraints (introduction of FDA Modernization Act 2.0/3.0, stringent regulatory compliance for ethical use of animal models), opportunities (growing preference for humanized PDX models, emergence of CRISPR in biomedical research), and challenges (alternatives for animal testing, limitations of humanized mouse models) influencing market growth.
• Product Development/Innovation: Detailed insights on upcoming technologies in humanized mouse and rat models, research and development activities, and new product launches in the humanized mouse and rat model market.
• Market Development: Comprehensive information about lucrative markets-the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the humanized mouse and rat model market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players such as Charles River Laboratories (US), The Jackson Laboratory (JAX) (US), Inotiv (US), and genOway (France).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 INCLUSIONS AND EXCLUSIONS
• 1.4 STUDY SCOPE
  • 1.4.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.4.2 YEARS CONSIDERED
  • 1.4.3 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
  • 2.2.2 SEGMENTAL MARKET ESTIMATION
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 HUMANIZED MOUSE AND RAT MODEL MARKET OVERVIEW
• 4.2 NORTH AMERICA: HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER AND COUNTRY, 2024
• 4.3 HUMANIZED MOUSE AND RAT MODEL MARKET, BY KEY COUNTRY
• 4.4 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising use of humanized models in drug discovery research
    • 5.2.1.2 Emerging preclinical applications of humanized mouse models
    • 5.2.1.3 Government-funded initiatives for cancer research
    • 5.2.1.4 Increasing R&D activities in pharmaceutical & biotechnology industry
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Introduction of FDA Modernization Act 2.0/3.0
    • 5.2.2.2 Stringent regulatory compliance for ethical use of animal models
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing preference for humanized PDX models
    • 5.2.3.2 Emergence of CRISPR in biomedical research
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Alternative methods for animal testing
    • 5.2.4.2 Limitations of humanized mouse models
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE TREND OF KEY PRODUCTS, BY REGION
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 CRISPR-Cas9
    • 5.9.1.2 Tissue engineering
    • 5.9.1.3 In vivo imaging
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 3D cell culture
    • 5.9.2.2 Organs-on-Chips
    • 5.9.2.3 Biomarker discovery
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Proteomics
    • 5.9.3.2 Microfluidics
    • 5.9.3.3 Regenerative medicine
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 REGULATORY LANDSCAPE
  • 5.13.1 REGULATORY FRAMEWORK
  • 5.13.2 NORTH AMERICA
  • 5.13.3 EUROPE
  • 5.13.4 ASIA PACIFIC
    • 5.13.4.1 China
    • 5.13.4.2 Japan
    • 5.13.4.3 India
    • 5.13.4.4 Australia
  • 5.13.5 LATIN AMERICA
  • 5.13.6 MIDDLE EAST & AFRICA
  • 5.13.7 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.14 PORTER'S FIVE FORCES ANALYSIS
  • 5.14.1 THREAT OF NEW ENTRANTS
  • 5.14.2 THREAT OF SUBSTITUTES
  • 5.14.3 BARGAINING POWER OF SUPPLIERS
  • 5.14.4 BARGAINING POWER OF BUYERS
  • 5.14.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.15 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.15.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.15.2 KEY BUYING CRITERIA, BY END USER
• 5.16 IMPACT OF AI ON HUMANIZED MOUSE AND RAT MODEL MARKET
  • 5.16.1 INTRODUCTION
  • 5.16.2 MARKET POTENTIAL OF AI IN HUMANIZED MOUSE AND RAT MODELS
  • 5.16.3 AI USE CASES
  • 5.16.4 KEY COMPANIES IMPLEMENTING AI
  • 5.16.5 FUTURE OF GENERATIVE AI IN HUMANIZED MOUSE AND RAT MODEL MARKET

6 HUMANIZED MOUSE AND RAT MODEL MARKET, BY TYPE

• 6.1 INTRODUCTION
• 6.2 HUMANIZED MOUSE MODELS
  • 6.2.1 GENETIC HUMANIZED MOUSE MODELS
    • 6.2.1.1 Advancements in genetical engineering technologies to drive market
  • 6.2.2 CELL-BASED HUMANIZED MOUSE MODELS
    • 6.2.2.1 CD34 humanized mouse models
      • 6.2.2.1.1 Rising demand for stem cell therapy to propel market
    • 6.2.2.2 PBMC humanized mouse models
      • 6.2.2.2.1 Growing prevalence of infectious diseases to boost demand
    • 6.2.2.3 BLT humanized mouse models
      • 6.2.2.3.1 Surge in HIV cases to drive market
• 6.3 HUMANIZED RAT MODELS
  • 6.3.1 PREFERENCE FOR SRG RAT MODELS FOR RESEARCH STUDIES WITH LARGE SAMPLE SIZE SUPPORTS THE SEGMENT GROWTH

7 HUMANIZED MOUSE AND RAT MODEL MARKET, BY END USER

• 7.1 INTRODUCTION
• 7.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 7.2.1 GROWING ADOPTION OF HU-MICE MODELS IN VACCINE DEVELOPMENT TO BOOST SEGMENT GROWTH
• 7.3 CONTRACT RESEARCH ORGANIZATIONS AND CONTRACT DEVELOPMENT MANUFACTURING ORGANIZATIONS
  • 7.3.1 OUTSOURCING OF DRUG DISCOVERY SERVICES BY PHARMA & BIOTECH COMPANIES TO PROPEL MARKET
• 7.4 ACADEMIC & RESEARCH INSTITUTES
  • 7.4.1 SUPPORTIVE FUNDING INVESTMENTS FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET

8 HUMANIZED MOUSE AND RAT MODEL MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ONCOLOGY
  • 8.2.1 UTILIZATION OF MOUSE MODELS IN CANCER RESEARCH TO DRIVE MARKET
• 8.3 IMMUNOLOGY AND INFECTIOUS DISEASES
  • 8.3.1 DEVELOPMENT OF ADVANCED MODELS FOR TREATMENT OF RARE DISEASES TO DRIVE MARKET
• 8.4 NEUROSCIENCE
  • 8.4.1 RISING INCIDENCE OF CNS DISORDERS TO DRIVE MARKET
• 8.5 TOXICOLOGY
  • 8.5.1 INCREASING CLINICAL TRIALS FOR TOXICOLOGY STUDIES TO SUPPORT MARKET GROWTH
• 8.6 HEMATOPOIESIS
  • 8.6.1 RISING DEMAND FOR STEM CELL THERAPY TO DRIVE MARKET
• 8.7 OTHER APPLICATIONS

9 HUMANIZED MOUSE AND RAT MODEL MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK OF NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 Growing research initiatives on mAbs and biosimilars to drive market
  • 9.2.3 CANADA
    • 9.2.3.1 Government initiatives on stem cell research to drive market
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK OF EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Rising pharmaceutical R&D expenditure to drive market
  • 9.3.3 UK
    • 9.3.3.1 Growing investments in cancer research to drive market
  • 9.3.4 FRANCE
    • 9.3.4.1 Rising initiatives for genomics research to support market growth
  • 9.3.5 ITALY
    • 9.3.5.1 Robust pharmaceutical production to fuel market
  • 9.3.6 SPAIN
    • 9.3.6.1 Rising growth in biotech industry to drive market
  • 9.3.7 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK OF ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 High growth in pharmaceutical industry to drive market
  • 9.4.3 JAPAN
    • 9.4.3.1 Growing research collaborations among pharmaceutical companies to drive market
  • 9.4.4 INDIA
    • 9.4.4.1 Growth in biotech industry to drive market
  • 9.4.5 SOUTH KOREA
    • 9.4.5.1 Rising government-funded investments for pharmaceutical R&D to drive market
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Rising biomedical research projects to drive market
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 GROWING PRESENCE OF PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO PROPEL MARKET
  • 9.5.2 MACROECONOMIC OUTLOOK OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 GROWING PHARMACEUTICAL MARKET IN COUNTRIES TO SUPPORT MARKET GROWTH
  • 9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 GROWING PHARMACEUTICAL INDUSTRY TO SUPPORT MARKET GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGY/RIGHT TO WIN
  • 10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN HUMANIZED MOUSE AND RAT MODEL MARKET
• 10.3 REVENUE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.4.1 HUMANIZED MOUSE AND RAT MODEL MARKET
• 10.5 COMPANY VALUATION AND FINANCIAL METRICS
  • 10.5.1 FINANCIAL METRICS
• 10.6 BRAND/PRODUCT COMPARISON
• 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.7.1 STARS
  • 10.7.2 EMERGING LEADERS
  • 10.7.3 PERVASIVE PLAYERS
  • 10.7.4 PARTICIPANTS
  • 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.7.5.1 Company footprint
    • 10.7.5.2 Region footprint
    • 10.7.5.3 Type footprint
    • 10.7.5.4 Application footprint
• 10.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 10.8.1 PROGRESSIVE COMPANIES
  • 10.8.2 RESPONSIVE COMPANIES
  • 10.8.3 DYNAMIC COMPANIES
  • 10.8.4 STARTING BLOCKS
  • 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES
    • 10.8.5.1 Detailed list of key startups/SMEs
    • 10.8.5.2 Competitive benchmarking of key startups/SMEs
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES & APPROVALS
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 CHARLES RIVER LABORATORIES
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
      • 11.1.1.3.2 Other developments
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 THE JACKSON LABORATORY
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 INOTIV
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Deals
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 GENOWAY
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Other developments
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 TACONIC BIOSCIENCES, INC.
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Product launches
      • 11.1.5.3.2 Expansions
  • 11.1.6 JSR CORPORATION
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Deals
      • 11.1.6.3.2 Expansions
  • 11.1.7 CHAMPIONS ONCOLOGY, INC.
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products offered
  • 11.1.8 JANVIER LABS
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
  • 11.1.9 VITALSTAR BIOTECHNOLOGY
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products offered
  • 11.1.10 INGENIOUS TARGETING LABORATORY
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products offered
  • 11.1.11 HARBOUR BIOMED
    • 11.1.11.1 Business overview
    • 11.1.11.2 Products offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
  • 11.1.12 ONCODESIGN SERVICES
    • 11.1.12.1 Business overview
    • 11.1.12.2 Products offered
  • 11.1.13 PHARMATEST SERVICES
    • 11.1.13.1 Business overview
    • 11.1.13.2 Products offered
• 11.2 OTHER PLAYERS
  • 11.2.1 OZGENE PTY LTD.
  • 11.2.2 CLEA JAPAN, INC.
  • 11.2.3 ALTOGEN LABS
  • 11.2.4 REACTION BIOLOGY
  • 11.2.5 TRANSCURE BIOSERVICES
  • 11.2.6 CYAGEN
  • 11.2.7 ARAGEN LIFE SCIENCES LTD.
  • 11.2.8 BIOCYTOGEN
  • 11.2.9 GEMPHARMATECH

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS

관련자료